Litcius/Paper detail

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael Bishop, Lloyd E. Damon, S.R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie José Kersten, Monalisa Ghosh, Nina D. Wagner‐Johnston, Koji Kato, Paolo Corradini, Marcela Martínez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T. Maziarz

2021The Lancet Oncology562 citationsDOI

Topics & Concepts

MedicineClinical endpointInternal medicineRefractory (planetary science)Cytokine release syndromeOncologyHematopoietic stem cell transplantationChimeric antigen receptorCohortTransplantationClinical trialImmunotherapyCancerBiologyAstrobiologyCAR-T cell therapy researchVirus-based gene therapy researchImmunotherapy and Immune Responses